FDA
-
-
-
-
-
-
-
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
-
-
-
-
-
-
-
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
-
-
-
-
-
-
-
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
-
-
-
-
-
-
-
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
-
-
-
-
-
-
-
Lumos Pharma, Inc. (LUMO) Announces KOL Review of Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
-
-
-
-
-
-
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
-
-
-
-
-
-
-
Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
251,761 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All